A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma

Qunfeng Wu, Liya Pi, Thu Le Trinh, Chaohui Zuo, Man Xia, Yu Jiao, Zhouhua Hou, Sung Jo, William Puszyk, Kien Pham, David R. Nelson, Keith D Robertson, David Ostrov, Pranela Rameshwar, Chang Qing Xia, Chen Liu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) has a high morbidity and mortality rate worldwide, with limited treatment options. Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored glycoprotein that is overexpressed in most HCC tissues but not in normal tissues. GPC3-targeting antibody therapy shows limited response in a clinical trial due to the lack of a tumor-specific cytotoxic T lymphocyte (CTL) response. Here, in C57/B6 mice, we demonstrated that intravenous infusion of GPC3-coupled lymphocytes (LC/GPC3+) elicited robust GPC3-specific antibody and CTL responses, which effectively restricted proliferation and lysed cultured-HCC cells. Treatment with LC/GPC3+ induced durable tumor regression in HCC-bearing C57/B6 mice. Administration of LC/GPC3+ induced elevated levels of the cytotoxic T cell bioactive factors tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ), granzyme B, and perforin, and substantially increased the number of infiltrating CD8+ T cells in tumor tissues. Moreover, immune responses elicited by LC/GPC3+ selectively suppressed GPC3+ tumors, but didn't affect the GPC3- tumors in BALB/c mice. Our findings provide the first preclinical evidence that intravenous infusion of the LC/GPC3+ complex can induce a strong anti-HCC effect through regulating systemic and local immune responses. These results indicate that the LC/GPC3+ complex could be developed as precision therapeutics for HCC patients in the future. Wu et al. develop a novel immunotherapeutic vaccine for hepatocellular carcinoma (HCC) treatment through targeting the HCC-specific antigen GPC3. The antigen GPC3 is coupled on and delivered through lymphocytes. The lymphocyte-GPC3 complex vaccine triggers significantly prophylactic and therapeutic antitumor effects in the murine model through regulating systemic and local immune responses.

Original languageEnglish (US)
JournalMolecular Therapy
DOIs
StateAccepted/In press - 2017

Fingerprint

Glypicans
Hepatocellular Carcinoma
Vaccines
Therapeutics
Cytotoxic T-Lymphocytes
Lymphocytes
Neoplasms
Intravenous Infusions
TCF Transcription Factors
Antigens
Glycosylphosphatidylinositols
Antibodies

Keywords

  • Cytotoxic T lymphocyte response
  • Glypican-3
  • Hepatocellular carcinoma
  • Immunotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Wu, Q., Pi, L., Le Trinh, T., Zuo, C., Xia, M., Jiao, Y., ... Liu, C. (Accepted/In press). A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.08.005

A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. / Wu, Qunfeng; Pi, Liya; Le Trinh, Thu; Zuo, Chaohui; Xia, Man; Jiao, Yu; Hou, Zhouhua; Jo, Sung; Puszyk, William; Pham, Kien; Nelson, David R.; Robertson, Keith D; Ostrov, David; Rameshwar, Pranela; Xia, Chang Qing; Liu, Chen.

In: Molecular Therapy, 2017.

Research output: Contribution to journalArticle

Wu, Q, Pi, L, Le Trinh, T, Zuo, C, Xia, M, Jiao, Y, Hou, Z, Jo, S, Puszyk, W, Pham, K, Nelson, DR, Robertson, KD, Ostrov, D, Rameshwar, P, Xia, CQ & Liu, C 2017, 'A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma', Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.08.005
Wu, Qunfeng ; Pi, Liya ; Le Trinh, Thu ; Zuo, Chaohui ; Xia, Man ; Jiao, Yu ; Hou, Zhouhua ; Jo, Sung ; Puszyk, William ; Pham, Kien ; Nelson, David R. ; Robertson, Keith D ; Ostrov, David ; Rameshwar, Pranela ; Xia, Chang Qing ; Liu, Chen. / A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. In: Molecular Therapy. 2017.
@article{fc69edb5e3dc4658b19a3b3db2a923e8,
title = "A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma",
abstract = "Hepatocellular carcinoma (HCC) has a high morbidity and mortality rate worldwide, with limited treatment options. Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored glycoprotein that is overexpressed in most HCC tissues but not in normal tissues. GPC3-targeting antibody therapy shows limited response in a clinical trial due to the lack of a tumor-specific cytotoxic T lymphocyte (CTL) response. Here, in C57/B6 mice, we demonstrated that intravenous infusion of GPC3-coupled lymphocytes (LC/GPC3+) elicited robust GPC3-specific antibody and CTL responses, which effectively restricted proliferation and lysed cultured-HCC cells. Treatment with LC/GPC3+ induced durable tumor regression in HCC-bearing C57/B6 mice. Administration of LC/GPC3+ induced elevated levels of the cytotoxic T cell bioactive factors tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ), granzyme B, and perforin, and substantially increased the number of infiltrating CD8+ T cells in tumor tissues. Moreover, immune responses elicited by LC/GPC3+ selectively suppressed GPC3+ tumors, but didn't affect the GPC3- tumors in BALB/c mice. Our findings provide the first preclinical evidence that intravenous infusion of the LC/GPC3+ complex can induce a strong anti-HCC effect through regulating systemic and local immune responses. These results indicate that the LC/GPC3+ complex could be developed as precision therapeutics for HCC patients in the future. Wu et al. develop a novel immunotherapeutic vaccine for hepatocellular carcinoma (HCC) treatment through targeting the HCC-specific antigen GPC3. The antigen GPC3 is coupled on and delivered through lymphocytes. The lymphocyte-GPC3 complex vaccine triggers significantly prophylactic and therapeutic antitumor effects in the murine model through regulating systemic and local immune responses.",
keywords = "Cytotoxic T lymphocyte response, Glypican-3, Hepatocellular carcinoma, Immunotherapy",
author = "Qunfeng Wu and Liya Pi and {Le Trinh}, Thu and Chaohui Zuo and Man Xia and Yu Jiao and Zhouhua Hou and Sung Jo and William Puszyk and Kien Pham and Nelson, {David R.} and Robertson, {Keith D} and David Ostrov and Pranela Rameshwar and Xia, {Chang Qing} and Chen Liu",
year = "2017",
doi = "10.1016/j.ymthe.2017.08.005",
language = "English (US)",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma

AU - Wu, Qunfeng

AU - Pi, Liya

AU - Le Trinh, Thu

AU - Zuo, Chaohui

AU - Xia, Man

AU - Jiao, Yu

AU - Hou, Zhouhua

AU - Jo, Sung

AU - Puszyk, William

AU - Pham, Kien

AU - Nelson, David R.

AU - Robertson, Keith D

AU - Ostrov, David

AU - Rameshwar, Pranela

AU - Xia, Chang Qing

AU - Liu, Chen

PY - 2017

Y1 - 2017

N2 - Hepatocellular carcinoma (HCC) has a high morbidity and mortality rate worldwide, with limited treatment options. Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored glycoprotein that is overexpressed in most HCC tissues but not in normal tissues. GPC3-targeting antibody therapy shows limited response in a clinical trial due to the lack of a tumor-specific cytotoxic T lymphocyte (CTL) response. Here, in C57/B6 mice, we demonstrated that intravenous infusion of GPC3-coupled lymphocytes (LC/GPC3+) elicited robust GPC3-specific antibody and CTL responses, which effectively restricted proliferation and lysed cultured-HCC cells. Treatment with LC/GPC3+ induced durable tumor regression in HCC-bearing C57/B6 mice. Administration of LC/GPC3+ induced elevated levels of the cytotoxic T cell bioactive factors tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ), granzyme B, and perforin, and substantially increased the number of infiltrating CD8+ T cells in tumor tissues. Moreover, immune responses elicited by LC/GPC3+ selectively suppressed GPC3+ tumors, but didn't affect the GPC3- tumors in BALB/c mice. Our findings provide the first preclinical evidence that intravenous infusion of the LC/GPC3+ complex can induce a strong anti-HCC effect through regulating systemic and local immune responses. These results indicate that the LC/GPC3+ complex could be developed as precision therapeutics for HCC patients in the future. Wu et al. develop a novel immunotherapeutic vaccine for hepatocellular carcinoma (HCC) treatment through targeting the HCC-specific antigen GPC3. The antigen GPC3 is coupled on and delivered through lymphocytes. The lymphocyte-GPC3 complex vaccine triggers significantly prophylactic and therapeutic antitumor effects in the murine model through regulating systemic and local immune responses.

AB - Hepatocellular carcinoma (HCC) has a high morbidity and mortality rate worldwide, with limited treatment options. Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored glycoprotein that is overexpressed in most HCC tissues but not in normal tissues. GPC3-targeting antibody therapy shows limited response in a clinical trial due to the lack of a tumor-specific cytotoxic T lymphocyte (CTL) response. Here, in C57/B6 mice, we demonstrated that intravenous infusion of GPC3-coupled lymphocytes (LC/GPC3+) elicited robust GPC3-specific antibody and CTL responses, which effectively restricted proliferation and lysed cultured-HCC cells. Treatment with LC/GPC3+ induced durable tumor regression in HCC-bearing C57/B6 mice. Administration of LC/GPC3+ induced elevated levels of the cytotoxic T cell bioactive factors tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ), granzyme B, and perforin, and substantially increased the number of infiltrating CD8+ T cells in tumor tissues. Moreover, immune responses elicited by LC/GPC3+ selectively suppressed GPC3+ tumors, but didn't affect the GPC3- tumors in BALB/c mice. Our findings provide the first preclinical evidence that intravenous infusion of the LC/GPC3+ complex can induce a strong anti-HCC effect through regulating systemic and local immune responses. These results indicate that the LC/GPC3+ complex could be developed as precision therapeutics for HCC patients in the future. Wu et al. develop a novel immunotherapeutic vaccine for hepatocellular carcinoma (HCC) treatment through targeting the HCC-specific antigen GPC3. The antigen GPC3 is coupled on and delivered through lymphocytes. The lymphocyte-GPC3 complex vaccine triggers significantly prophylactic and therapeutic antitumor effects in the murine model through regulating systemic and local immune responses.

KW - Cytotoxic T lymphocyte response

KW - Glypican-3

KW - Hepatocellular carcinoma

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85028511012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028511012&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2017.08.005

DO - 10.1016/j.ymthe.2017.08.005

M3 - Article

C2 - 28865999

AN - SCOPUS:85028511012

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

ER -